UK markets closed

Neurocrine Biosciences, Inc. (0K6R.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
105.00+2.15 (+2.09%)
At close: 5:55PM BST
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3N/A
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) 0.72
52-week change 3N/A
S&P500 52-week change 330.48%
52-week high 3105.00
52-week low 3105.00
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 590.68M
Implied shares outstanding 6N/A
Float 893.4M
% held by insiders 11.35%
% held by institutions 1100.28%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)30 Jun 2021

Profitability

Profit margin 35.34%
Operating margin (ttm)23.77%

Management effectiveness

Return on assets (ttm)8.83%
Return on equity (ttm)34.56%

Income statement

Revenue (ttm)1.03B
Revenue per share (ttm)10.99
Quarterly revenue growth (yoy)-4.50%
Gross profit (ttm)760.8M
EBITDA 254.8M
Net income avi to common (ttm)364.7M
Diluted EPS (ttm)3.72
Quarterly earnings growth (yoy)-46.90%

Balance sheet

Total cash (mrq)884.9M
Total cash per share (mrq)9.35
Total debt (mrq)450.3M
Total debt/equity (mrq)35.20
Current ratio (mrq)5.21
Book value per share (mrq)13.52

Cash flow statement

Operating cash flow (ttm)264.6M
Levered free cash flow (ttm)285.75M